SEC Comment Letter for NextCure, Inc. (NXTC) (CIK 0001661059) (NXTC) — Nov 6, 2019

NextCure, Inc. (NXTC) (CIK 0001661059)
Date: Nov. 6, 2019 · CIK: 0001661059 · Accession: 0000000000-19-015264

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

Date

November 6, 2019

Author

Gregory Dundas

Form

UPLOAD

Company

NextCure, Inc. (NXTC) (CIK 0001661059)

Letter

November 6, 2019 Michael Richman Chief Executive Officer NextCure, Inc. 9000 Virginia Manor Road, Suite 200 Beltsville, Maryland 20705 Re:NextCure, Inc. Draft Registration Statement on Form S-1 Submitted on October 29, 2019 CIK No. 0001661059 Dear Mr. Richman: This is to advise you that we do not intend to review your registration statement. We request that you publicly file your registration statement no later than 48 hours prior to the requested effective date and time. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Gregory Dundas, Attorney Adviser, at (202) 551-3436 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: William Intner, Esq.

Show Raw Text

November 6, 2019
Michael Richman
Chief Executive Officer
NextCure, Inc.
9000 Virginia Manor Road, Suite 200
Beltsville, Maryland 20705
Re:NextCure, Inc.
Draft Registration Statement on Form S-1
Submitted on October 29, 2019
CIK No. 0001661059
Dear Mr. Richman:
            This is to advise you that we do not intend to review your registration statement.
            We request that you publicly file your registration statement no later than 48 hours prior
to the requested effective date and time. Please refer to Rules 460 and 461 regarding requests for
acceleration. We remind you that the company and its management are responsible for the
accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or
absence of action by the staff.
            Please contact Gregory Dundas, Attorney Adviser, at (202) 551-3436 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:       William Intner, Esq.

SecProbe.io